1. Home
  2. STEX vs RANI Comparison

STEX vs RANI Comparison

Compare STEX & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

STEX

Streamex Corp.

N/A

Current Price

$3.46

Market Cap

127.3M

Sector

N/A

ML Signal

N/A

Logo Rani Therapeutics Holdings Inc.

RANI

Rani Therapeutics Holdings Inc.

HOLD

Current Price

$1.40

Market Cap

132.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STEX
RANI
Founded
2009
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
127.3M
132.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
STEX
RANI
Price
$3.46
$1.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$12.00
$8.67
AVG Volume (30 Days)
713.5K
1.4M
Earning Date
02-17-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,000.00
$1,200,000.00
Revenue This Year
N/A
$414.59
Revenue Next Year
N/A
$30.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.40
$0.39
52 Week High
$14.11
$3.87

Technical Indicators

Market Signals
Indicator
STEX
RANI
Relative Strength Index (RSI) N/A 46.42
Support Level N/A $1.31
Resistance Level N/A $1.44
Average True Range (ATR) 0.00 0.08
MACD 0.00 0.01
Stochastic Oscillator 0.00 43.14

Price Performance

Historical Comparison
STEX
RANI

About STEX Streamex Corp.

Streamex Corp is a vertically integrated technology and infrastructure company. It is focused on the tokenization and digitalization of real-world assets. The group provides institutional-grade solutions that bring traditional commodities and assets on-chain through secure, regulated, and yield-bearing financial instruments. It is committed to delivering transparent, scalable, and compliant digital asset solutions that bridge the gap between traditional finance and blockchain-enabled markets.

About RANI Rani Therapeutics Holdings Inc.

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

Share on Social Networks: